Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

I've read this elsewhere. Glad to see there is a peer reviewed poster on the Phase 2 trial:

Results: A total of 215 patients were randomized in three countries (Canada; Russia; Ukraine). Analysis populations included ITT (N=215); mITT(N=172); Per Protocol(N=161); and Safety (N=215). Clinical response rates in the PP population (N=161) are given below (see table). Efficacy results were consistent in the ITT and mITT populations. Numbness/tingling (N/T), the most frequently reported adverse event (AE), occurred in 65%, 65%, 87%, and 2%, respectively, in the Low, Med, High and dapto groups. These events were transient, mild, and did not lead to any discontinuations.

In an earlier post you confused Brilacidin results with Dalparatag. It was Dalparatag that had BP problems and not Brilacidin. I'm disappointed that no one else corrected you on that error among other you have posted as "facts" today.

Your notion that Brilacidin is noninferior is not correct. It has fewer issues than the current standard. That makes it superior when combined with equal efficacy outcomes. Noninferior takes into account all counter indications along with efficacy.